Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Friberg LE"" wg kryterium: Autor


Tytuł:
Multistate modeling for survival analysis in critically ill patients treated with meropenem.
Autorzy:
Peng Y; Department of Pharmacy, Uppsala University, Uppsala, Sweden.; Division of Biopharmaceutics and Pharmacokinetics, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
Minichmayr IK; Department of Pharmacy, Uppsala University, Uppsala, Sweden.; Department of Clinical Pharmacology, Medical University Vienna, Vienna, Austria.
Liu H; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Xie F; Division of Biopharmaceutics and Pharmacokinetics, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
Friberg LE; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Feb; Vol. 13 (2), pp. 222-233. Date of Electronic Publication: 2023 Nov 07.
Typ publikacji:
Journal Article
MeSH Terms:
Critical Illness*/therapy
Anti-Bacterial Agents*
Humans ; Meropenem/pharmacology ; Microbial Sensitivity Tests
Czasopismo naukowe
Tytuł:
Model-based assessment of neutrophil-mediated phagocytosis and digestion of bacteria across in vitro and in vivo studies.
Autorzy:
Thorsted A; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Pham AD
Friberg LE; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Nielsen EI; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Dec; Vol. 12 (12), pp. 1972-1987. Date of Electronic Publication: 2023 Oct 16.
Typ publikacji:
Journal Article
MeSH Terms:
Neutrophils*
Bacterial Infections*
Humans ; Mice ; Animals ; Phagocytosis ; Bacteria ; Digestion
Czasopismo naukowe
Tytuł:
A model-based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno-oncology.
Autorzy:
Sánchez J; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Claus C; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Zurich, Schlieren, Switzerland.
Albrecht R; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Zurich, Schlieren, Switzerland.
Gaillard BC; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Zurich, Schlieren, Switzerland.
Marinho J; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Zurich, Schlieren, Switzerland.
McIntyre C; Roche Pharma Research and Early Development, Roche Innovation Center Welwyn, Welwyn Garden City, UK.
Tanos T; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.
Boehnke A; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.
Friberg LE; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Jönsson S; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Frances N; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Nov; Vol. 12 (11), pp. 1804-1818. Date of Electronic Publication: 2023 Nov 15.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Bispecific*/pharmacology
Neoplasms*/drug therapy
Humans ; T-Lymphocytes/metabolism
Czasopismo naukowe
Tytuł:
A multistate modeling and simulation framework to learn dose-response of oncology drugs: Application to bintrafusp alfa in non-small cell lung cancer.
Autorzy:
Liu H; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Milenković-Grišić AM; Merck Healthcare KGaA, Darmstadt, Germany.
Krishnan SM; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Jönsson S; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Friberg LE; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Girard P; Merck Institute of Pharmacometrics, an affiliate of Merck KGaA, Lausanne, Switzerland.
Venkatakrishnan K; EMD Serono Research & Development Institute, Inc., an affiliate of Merck KGaA, Billerica, Massachusetts, USA.
Vugmeyster Y; EMD Serono Research & Development Institute, Inc., an affiliate of Merck KGaA, Billerica, Massachusetts, USA.
Khandelwal A; Merck Healthcare KGaA, Darmstadt, Germany.
Karlsson MO; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Nov; Vol. 12 (11), pp. 1738-1750. Date of Electronic Publication: 2023 May 11.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*
Lung Neoplasms*/pathology
Humans ; Progression-Free Survival ; Computer Simulation ; Probability ; B7-H1 Antigen/therapeutic use
Czasopismo naukowe
Tytuł:
Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic-pharmacodynamic models.
Autorzy:
Ibrahim EIK; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Karlsson MO; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Friberg LE; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Sep; Vol. 12 (9), pp. 1305-1318. Date of Electronic Publication: 2023 Jul 26.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Hypertension*
Humans ; Agammaglobulinaemia Tyrosine Kinase/metabolism ; Blood Pressure ; Leukocytes/metabolism ; Leukocytes/pathology
Czasopismo naukowe
Tytuł:
Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity.
Autorzy:
Svensson RJ; Pharmetheus AB, Uppsala, Sweden.
Ooi QX; Pharmetheus AB, Uppsala, Sweden.
Friberg LE; Pharmetheus AB, Uppsala, Sweden.; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Maharaj N; Dr. Reddy's Laboratories Ltd, Hyderabad, Telangana, India.
Reddy PK; Dr. Reddy's Laboratories Ltd, Hyderabad, Telangana, India.
López-Lázaro L; Dr. Reddy's Laboratories SA, Basel, Switzerland.
Hansson E; Pharmetheus AB, Uppsala, Sweden.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Feb; Vol. 12 (2), pp. 154-167. Date of Electronic Publication: 2022 Dec 25.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Biosimilar Pharmaceuticals*/pharmacokinetics
Biosimilar Pharmaceuticals*/therapeutic use
Humans ; Rituximab/pharmacokinetics ; Switzerland
Czasopismo naukowe
Tytuł:
Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors.
Autorzy:
Centanni M; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Thijs A; Department of Internal Medicine, Amsterdam UMC, Location VU University, Amsterdam, The Netherlands.
Desar I; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Karlsson MO; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Friberg LE; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2023 Jan; Vol. 16 (1), pp. 73-84. Date of Electronic Publication: 2022 Oct 18.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hypertension*/diagnosis
Hypertension*/drug therapy
Humans ; Blood Pressure ; Blood Pressure Monitoring, Ambulatory ; Blood Pressure Determination/methods ; Tyrosine
Czasopismo naukowe
Tytuł:
Bayesian forecasting of tumor size metrics and overall survival.
Autorzy:
Krishnan SM; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Friberg LE; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2022 Dec; Vol. 11 (12), pp. 1604-1613. Date of Electronic Publication: 2022 Oct 04.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Benchmarking*
Neoplasms*/drug therapy
Humans ; Bayes Theorem ; Computer Simulation
Czasopismo naukowe
Tytuł:
Publisher Correction: Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance.
Autorzy:
Yin A; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.; Leiden Network for Personalized Therapeutics, Leiden University Medical Center, Leiden, The Netherlands.
van Hasselt JGC; Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, The Netherlands.
Guchelaar HJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.; Leiden Network for Personalized Therapeutics, Leiden University Medical Center, Leiden, The Netherlands.
Friberg LE; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Moes DJAR; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. .; Leiden Network for Personalized Therapeutics, Leiden University Medical Center, Leiden, The Netherlands. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Mar 22; Vol. 12 (1), pp. 4879. Date of Electronic Publication: 2022 Mar 22.
Typ publikacji:
Published Erratum
Tytuł:
Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance.
Autorzy:
Yin A; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.; Leiden Network for Personalized Therapeutics, Leiden University Medical Center, Leiden, The Netherlands.
van Hasselt JGC; Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, The Netherlands.
Guchelaar HJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.; Leiden Network for Personalized Therapeutics, Leiden University Medical Center, Leiden, The Netherlands.
Friberg LE; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Moes DJAR; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. .; Leiden Network for Personalized Therapeutics, Leiden University Medical Center, Leiden, The Netherlands. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Mar 10; Vol. 12 (1), pp. 4206. Date of Electronic Publication: 2022 Mar 10.
Typ publikacji:
Journal Article
MeSH Terms:
Circulating Tumor DNA*/genetics
Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/genetics
Colorectal Neoplasms*/pathology
Biomarkers, Tumor/genetics ; Humans ; Mutation ; Prospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Multistate model for pharmacometric analyses of overall survival in HER2-negative breast cancer patients treated with docetaxel.
Autorzy:
Krishnan SM; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Friberg LE; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Bruno R; Clinical Pharmacology, Roche/Genentech, Marseille, France.
Beyer U; Biostatistics, F. Hoffmann-La-Roche Ltd, Basel, Switzerland.
Jin JY; Clinical Pharmacology Roche/Genentech, South San Francisco, California, USA.
Karlsson MO; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2021 Oct; Vol. 10 (10), pp. 1255-1266. Date of Electronic Publication: 2021 Aug 03.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Breast Neoplasms/*drug therapy
Docetaxel/*therapeutic use
Receptor, ErbB-2/*metabolism
Adult ; Age Factors ; Aged ; Aged, 80 and over ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Female ; Humans ; Male ; Middle Aged ; Models, Statistical ; Progression-Free Survival ; Proportional Hazards Models ; Survival Rate ; Tumor Burden
Czasopismo naukowe
Tytuł:
Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel.
Autorzy:
van Doorn L; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
van Rosmalen MM; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
van der Deure WM; Department of Medical Oncology, Groene Hart Hospital, 2803 HH Gouda, The Netherlands.
Oomen-de Hoop E; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
Porrazzo R; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
Wijngaard SM; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
Boere IA; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
Veenstra P; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
Ibrahim E; Department of Pharmacy, Uppsala University, 751 24 Uppsala, Sweden.
de Bruijn P; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
Friberg LE; Department of Pharmacy, Uppsala University, 751 24 Uppsala, Sweden.
Koolen SLW; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
Jager A; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2021 Aug 03; Vol. 13 (15). Date of Electronic Publication: 2021 Aug 03.
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
CPT: Pharmacometrics & Systems Pharmacology - Inception, Maturation, and Future Vision.
Autorzy:
Rowland Yeo K; Certara UK Ltd (Simcyp Division), Sheffield, UK.
Hennig S; Certara, Inc, Princeton, NJ, USA.
Krishnaswami S; Pfizer, Groton, CT, USA.
Strydom N; Department of Bioengineering and Therapeutic Sciences, School of Pharmacy, University of California, San Francisco, CA, USA.
Ayyar VS; Janssen Research & Development, LLC, Spring House, PA, USA.
French J; Metrum Research Group, Tariffville, CT, USA.
Sinha V; Takeda, Cambridge, MA, USA.
Sobie E; Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Zhao P; Bill & Melinda Gates Foundation, Seattle, WA, USA.
Friberg LE; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Mentré F; IAME, INSERM, Université de Paris, Paris, France.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2021 Jul; Vol. 10 (7), pp. 649-657.
Typ publikacji:
Editorial
MeSH Terms:
Network Pharmacology*
Periodicals as Topic/*trends
Computational Biology ; Humans ; Models, Biological
Opinia redakcyjna
Tytuł:
Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2-negative breast cancer patients treated with docetaxel.
Autorzy:
Krishnan SM; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Laarif SS; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Bender BC; Genentech Inc., San Francisco, California, USA.
Quartino AL; Genentech Inc., San Francisco, California, USA.
Friberg LE; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2021 May; Vol. 10 (5), pp. 511-521. Date of Electronic Publication: 2021 May 02.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Neoplasm Metastasis*
Patient-Specific Modeling*
Antineoplastic Agents/*therapeutic use
Breast Neoplasms/*drug therapy
Docetaxel/*therapeutic use
Receptor, ErbB-2/*metabolism
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/pharmacology ; Breast Neoplasms/pathology ; Docetaxel/pharmacology ; Female ; Humans ; Middle Aged
Czasopismo naukowe
Tytuł:
Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity.
Autorzy:
Daitch V; Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Tel Aviv, Israel. .; Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Jebotinski 39, Petah Tikva, Israel. .
Paul M; Institute of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel.; The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
Daikos GL; First Department of Medicine, Laikon General Hospital, Athens, Greece.; National and Kapodistrian University of Athens, Athens, Greece.
Durante-Mangoni E; Internal Medicine, University of Campania 'L Vanvitelli', and AORN dei Colli-Monaldi Hospital, Naples, Italy.
Yahav D; Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Tel Aviv, Israel.; Unit of Infectious Diseases, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.
Carmeli Y; Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Tel Aviv, Israel.; Division of Epidemiology and Preventive Medicine, Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel.; National Institute for Antibiotic Resistance and Infection Control, Ministry of Health, Tel Aviv, Israel.
Benattar YD; Internal Medicine, University of Campania 'L Vanvitelli', and AORN dei Colli-Monaldi Hospital, Naples, Italy.; Cheryl Spencer Department of Nursing, University of Haifa, Haifa, Israel.
Skiada A; First Department of Medicine, Laikon General Hospital, Athens, Greece.; National and Kapodistrian University of Athens, Athens, Greece.
Andini R; Internal Medicine, University of Campania 'L Vanvitelli', and AORN dei Colli-Monaldi Hospital, Naples, Italy.
Eliakim-Raz N; Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Tel Aviv, Israel.; Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Jebotinski 39, Petah Tikva, Israel.
Nutman A; Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Tel Aviv, Israel.; National Institute for Antibiotic Resistance and Infection Control, Ministry of Health, Tel Aviv, Israel.
Zusman O; Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Tel Aviv, Israel.; Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Jebotinski 39, Petah Tikva, Israel.
Antoniadou A; National and Kapodistrian University of Athens, Athens, Greece.; Fourth Department of Medicine, Attikon University General Hospital, Athens, Greece.
Cavezza G; Internal Medicine, University of Campania 'L Vanvitelli', and AORN dei Colli-Monaldi Hospital, Naples, Italy.
Adler A; Microbiology Laboratory, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Dickstein Y; Institute of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel.
Pavleas I; Intensive Care Unit, Laikon General Hospital, Athens, Greece.
Zampino R; Internal Medicine, University of Campania 'L Vanvitelli', and AORN dei Colli-Monaldi Hospital, Naples, Italy.
Bitterman R; Institute of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel.; The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
Zayyad H; Institute of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel.
Koppel F; Institute of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel.
Zak-Doron Y; Institute of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel.
Levi I; Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Tel Aviv, Israel.; National Institute for Antibiotic Resistance and Infection Control, Ministry of Health, Tel Aviv, Israel.
Babich T; Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Tel Aviv, Israel.; Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Jebotinski 39, Petah Tikva, Israel.
Turjeman A; Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Tel Aviv, Israel.; Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Jebotinski 39, Petah Tikva, Israel.
Ben-Zvi H; Clinical Microbiology Laboratory, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.
Friberg LE; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Mouton JW; Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands.
Theuretzbacher U; Center for Anti-Infective Agents, Vienna, Austria.
Leibovici L; Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Tel Aviv, Israel.; Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Jebotinski 39, Petah Tikva, Israel.
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2021 Mar 31; Vol. 21 (1), pp. 309. Date of Electronic Publication: 2021 Mar 31.
Typ publikacji:
Comparative Study; Journal Article
MeSH Terms:
Drug Resistance, Bacterial*
Acinetobacter Infections/*drug therapy
Anti-Bacterial Agents/*therapeutic use
Acinetobacter Infections/microbiology ; Acinetobacter baumannii/isolation & purification ; Aged ; Carbapenems/therapeutic use ; Colistin/therapeutic use ; Female ; Greece ; Humans ; Israel ; Italy ; Logistic Models ; Male ; Meropenem/therapeutic use ; Middle Aged ; Randomized Controlled Trials as Topic ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Tumor Time-Course Predicts Overall Survival in Non-Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow-Up Time.
Autorzy:
Netterberg I; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Bruno R; Department of Clinical Pharmacology, Genentech-Roche, Marseille, France.
Chen YC; Department of Clinical Pharmacology, Genentech, South San Francisco, California, USA.
Winter H; Department of Clinical Pharmacology, Genentech, South San Francisco, California, USA.
Li CC; Department of Clinical Pharmacology, Genentech, South San Francisco, California, USA.
Jin JY; Department of Clinical Pharmacology, Genentech, South San Francisco, California, USA.
Friberg LE; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2020 Feb; Vol. 9 (2), pp. 115-123. Date of Electronic Publication: 2020 Jan 28.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal, Humanized/*administration & dosage
Antineoplastic Agents/*administration & dosage
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Antibodies, Monoclonal, Humanized/pharmacokinetics ; Antibodies, Monoclonal, Humanized/pharmacology ; Antineoplastic Agents/pharmacokinetics ; Biomarkers, Tumor/metabolism ; Clinical Trials, Phase I as Topic ; Follow-Up Studies ; Humans ; Lung Neoplasms/pathology ; Models, Biological ; Survival Rate ; Time Factors
Czasopismo naukowe
Tytuł:
A non-linear mixed effect model for innate immune response: In vivo kinetics of endotoxin and its induction of the cytokines tumor necrosis factor alpha and interleukin-6.
Autorzy:
Thorsted A; Pharmacometrics Research Group, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Bouchene S; Pharmacometrics Research Group, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Tano E; Section of Clinical Microbiology and Infectious Medicine, Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden.
Castegren M; Section of Infectious Diseases, Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden.; Division of Perioperative Medicine and Intensive Care, Karolinska University Hospital, Stockholm, Sweden.; Department of Clinical Science, Intervention and Technology, Karolinska Institute, Stockholm, Sweden.
Lipcsey M; Hedenstierna Laboratory, Section of Anesthesiology and Intensive Care, Department of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden.
Sjölin J; Section of Infectious Diseases, Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden.
Karlsson MO; Pharmacometrics Research Group, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Friberg LE; Pharmacometrics Research Group, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Nielsen EI; Pharmacometrics Research Group, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2019 Feb 21; Vol. 14 (2), pp. e0211981. Date of Electronic Publication: 2019 Feb 21 (Print Publication: 2019).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Endotoxemia/*immunology
Endotoxins/*administration & dosage
Escherichia coli/*metabolism
Interleukin-6/*blood
Tumor Necrosis Factor-alpha/*blood
Animals ; Computer Simulation ; Disease Models, Animal ; Endotoxemia/blood ; Endotoxins/immunology ; Immunity, Innate ; Infusions, Intravenous ; Nonlinear Dynamics ; Spatio-Temporal Analysis ; Swine
Czasopismo naukowe
Tytuł:
Association between Paclitaxel Clearance and Tumor Response in Patients with Esophageal Cancer.
Autorzy:
Toxopeus ELA; Department of Surgery, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. .
de Man FM; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. .
Krak N; Department of Radiology, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. nc_.
Biermann K; Department of Pathology, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. .
Nieuweboer AJM; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. .
Friberg LE; Department of Pharmaceutical Biosciences, Uppsala University, Box 256, 751 05 Uppsala, Sweden. lena.friberg@farmbio.uu.se.
Oomen-de Hoop E; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. .
van Lanschot JJB; Department of Surgery, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. .
Shapiro J; Department of Surgery, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. .
Wijnhoven BPL; Department of Surgery, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. .
Mathijssen RHJ; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. .
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2019 Feb 01; Vol. 11 (2). Date of Electronic Publication: 2019 Feb 01.
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
A Whole-Body Physiologically Based Pharmacokinetic Model for Colistin and Colistin Methanesulfonate in Rat.
Autorzy:
Bouchene S; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Marchand S; INSERM U-1070, Pôle Biologie Santé, Poitiers, France.; Laboratoire de Toxicologie et Pharmacocinétique, CHU de Poitiers, Poitiers, France.
Couet W; INSERM U-1070, Pôle Biologie Santé, Poitiers, France.; Laboratoire de Toxicologie et Pharmacocinétique, CHU de Poitiers, Poitiers, France.
Friberg LE; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Gobin P; INSERM U-1070, Pôle Biologie Santé, Poitiers, France.
Lamarche I; INSERM U-1070, Pôle Biologie Santé, Poitiers, France.
Grégoire N; INSERM U-1070, Pôle Biologie Santé, Poitiers, France.; Laboratoire de Toxicologie et Pharmacocinétique, CHU de Poitiers, Poitiers, France.
Björkman S; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Karlsson MO; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Pokaż więcej
Źródło:
Basic & clinical pharmacology & toxicology [Basic Clin Pharmacol Toxicol] 2018 Oct; Vol. 123 (4), pp. 407-422. Date of Electronic Publication: 2018 Jun 08.
Typ publikacji:
Comparative Study; Journal Article
MeSH Terms:
Models, Biological*
Anti-Bacterial Agents/*pharmacokinetics
Colistin/*analogs & derivatives
Prodrugs/*pharmacokinetics
Activation, Metabolic ; Animals ; Anti-Bacterial Agents/administration & dosage ; Colistin/administration & dosage ; Colistin/pharmacokinetics ; Computer Simulation ; Injections, Intravenous ; Male ; Prodrugs/administration & dosage ; Rats, Sprague-Dawley ; Tissue Distribution
Czasopismo naukowe
Tytuł:
Item Response Theory to Quantify Longitudinal Placebo and Paliperidone Effects on PANSS Scores in Schizophrenia.
Autorzy:
Krekels E; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Novakovic AM; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Vermeulen AM; Janssen Research & Development, a division of Janssen Pharmaceutica NV, Beerse, Belgium.
Friberg LE; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Karlsson MO; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2017 Aug; Vol. 6 (8), pp. 543-551. Date of Electronic Publication: 2017 Jul 13.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Schizophrenic Psychology*
Schizophrenia/*drug therapy
Adult ; Aged ; Clinical Trials, Phase III as Topic ; Double-Blind Method ; Female ; Humans ; Longitudinal Studies ; Male ; Middle Aged ; Paliperidone Palmitate ; Placebo Effect ; Psychiatric Status Rating Scales ; Randomized Controlled Trials as Topic ; Treatment Outcome ; Young Adult
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies